Company news
Clover Biopharmaceuticals Ltd. (HKEX:2197) news
Clover Biopharmaceuticals Ltd. news releases on 6ix. Latest, Sep 30, 2026: 2026 Interim Report
Press releases & updates
2026 Interim Report
September 30, 2026
Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults
September 6, 2026
Clover Announces Additional Positive U.S. Phase I Clinical Data for RSV Re-Vaccination in Older Adults
March 24, 2026
Clover Initiates Phase 2 Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
January 11, 2026
Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances
October 19, 2025
Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults
October 14, 2025
Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
June 17, 2025
Clover Announces U.S. IND Clearance and Initiation of Revaccination Clinical Study for RSV Vaccine Candidate SCB-1019
March 23, 2025
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVY
October 28, 2024
Clover Announces Positive Preliminary Phase Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults
June 19, 2024
Clover Announces Positive Preliminary Phase Ⅰ Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults
June 18, 2024
Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort
April 8, 2024
Clover Initiates Phase Ⅰ Clinical Trial for RSV Vaccine Candidate
December 12, 2023
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China
September 11, 2023
Clover Provides Updates on Business and R&D Pipeline Development
July 10, 2023
Clover Expands Sales and Distribution Network for Upcoming Quadrivalent Seasonal Influenza Vaccine Launch in China
May 23, 2023
Clover Announces Corporate Updates and Full Year 2022 Financial Results
March 28, 2023
Clover Biopharmaceuticals Announces Corporate Updates and Full Year 2022 Financial Results
March 29, 2023
Clover Enters into Exclusive Agreement to Commercialize Quadrivalent Seasonal Influenza Vaccine in Mainland China
February 19, 2023
Clover Biopharmaceuticals Launches COVID-19 Booster Vaccine in the People's Republic of China
February 15, 2023
UPDATE -- Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China
February 14, 2023